IBDEI0WR ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14765,1,3,0)
 ;;=3^Hemiplegia after Unsp Crbvasc Dis,Right Dominant Side
 ;;^UTILITY(U,$J,358.3,14765,1,4,0)
 ;;=4^I69.951
 ;;^UTILITY(U,$J,358.3,14765,2)
 ;;=^5007561
 ;;^UTILITY(U,$J,358.3,14766,0)
 ;;=I69.953^^58^707^21
 ;;^UTILITY(U,$J,358.3,14766,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14766,1,3,0)
 ;;=3^Hemiplegia after Unsp Crbvasc Dis,Right Nondominant Side
 ;;^UTILITY(U,$J,358.3,14766,1,4,0)
 ;;=4^I69.953
 ;;^UTILITY(U,$J,358.3,14766,2)
 ;;=^5007562
 ;;^UTILITY(U,$J,358.3,14767,0)
 ;;=G81.92^^58^707^22
 ;;^UTILITY(U,$J,358.3,14767,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14767,1,3,0)
 ;;=3^Hemiplegia,Unspec Affecting Left Dominant Side
 ;;^UTILITY(U,$J,358.3,14767,1,4,0)
 ;;=4^G81.92
 ;;^UTILITY(U,$J,358.3,14767,2)
 ;;=^5004122
 ;;^UTILITY(U,$J,358.3,14768,0)
 ;;=G81.94^^58^707^23
 ;;^UTILITY(U,$J,358.3,14768,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14768,1,3,0)
 ;;=3^Hemiplegia,Unspec Affecting Left Nondominant Side
 ;;^UTILITY(U,$J,358.3,14768,1,4,0)
 ;;=4^G81.94
 ;;^UTILITY(U,$J,358.3,14768,2)
 ;;=^5004124
 ;;^UTILITY(U,$J,358.3,14769,0)
 ;;=G81.91^^58^707^24
 ;;^UTILITY(U,$J,358.3,14769,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14769,1,3,0)
 ;;=3^Hemiplegia,Unspec Affecting Right Dominant Side
 ;;^UTILITY(U,$J,358.3,14769,1,4,0)
 ;;=4^G81.91
 ;;^UTILITY(U,$J,358.3,14769,2)
 ;;=^5004121
 ;;^UTILITY(U,$J,358.3,14770,0)
 ;;=G81.93^^58^707^25
 ;;^UTILITY(U,$J,358.3,14770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14770,1,3,0)
 ;;=3^Hemiplegia,Unspec Affecting Right Nondominant Side
 ;;^UTILITY(U,$J,358.3,14770,1,4,0)
 ;;=4^G81.93
 ;;^UTILITY(U,$J,358.3,14770,2)
 ;;=^5004123
 ;;^UTILITY(U,$J,358.3,14771,0)
 ;;=I69.942^^58^707^42
 ;;^UTILITY(U,$J,358.3,14771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14771,1,3,0)
 ;;=3^Monoplg LL after Unsp Crbvasc Dis,Left Dominant Side
 ;;^UTILITY(U,$J,358.3,14771,1,4,0)
 ;;=4^I69.942
 ;;^UTILITY(U,$J,358.3,14771,2)
 ;;=^5133582
 ;;^UTILITY(U,$J,358.3,14772,0)
 ;;=I69.944^^58^707^43
 ;;^UTILITY(U,$J,358.3,14772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14772,1,3,0)
 ;;=3^Monoplg LL after Unsp Crbvasc Dis,Left Nondominant Side
 ;;^UTILITY(U,$J,358.3,14772,1,4,0)
 ;;=4^I69.944
 ;;^UTILITY(U,$J,358.3,14772,2)
 ;;=^5133585
 ;;^UTILITY(U,$J,358.3,14773,0)
 ;;=I69.941^^58^707^44
 ;;^UTILITY(U,$J,358.3,14773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14773,1,3,0)
 ;;=3^Monoplg LL after Unsp Crbvasc Dis,Right Dominant Side
 ;;^UTILITY(U,$J,358.3,14773,1,4,0)
 ;;=4^I69.941
 ;;^UTILITY(U,$J,358.3,14773,2)
 ;;=^5133581
 ;;^UTILITY(U,$J,358.3,14774,0)
 ;;=I69.943^^58^707^45
 ;;^UTILITY(U,$J,358.3,14774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14774,1,3,0)
 ;;=3^Monoplg LL after Unsp Crbvasc Dis,Right Nondominant Side
 ;;^UTILITY(U,$J,358.3,14774,1,4,0)
 ;;=4^I69.943
 ;;^UTILITY(U,$J,358.3,14774,2)
 ;;=^5133584
 ;;^UTILITY(U,$J,358.3,14775,0)
 ;;=G35.^^58^707^46
 ;;^UTILITY(U,$J,358.3,14775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14775,1,3,0)
 ;;=3^Multiple sclerosis
 ;;^UTILITY(U,$J,358.3,14775,1,4,0)
 ;;=4^G35.
 ;;^UTILITY(U,$J,358.3,14775,2)
 ;;=^79761
 ;;^UTILITY(U,$J,358.3,14776,0)
 ;;=G20.^^58^707^47
 ;;^UTILITY(U,$J,358.3,14776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14776,1,3,0)
 ;;=3^Parkinson's disease
 ;;^UTILITY(U,$J,358.3,14776,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,14776,2)
 ;;=^5003770
 ;;^UTILITY(U,$J,358.3,14777,0)
 ;;=R56.9^^58^707^6
